In particular, CD8 T immune cells are crucial in anticancer immune response [105], where a higher amount of CD8 T-infiltrating lymphocytes (TILs) predicts a better immunotherapy response [106] and high levels of CD8 T-cells in samples correlate with better BC prognosis [53]. This evidence concerns the gene CD8A and breast cancer.